BioSpace News Archive

Oral presentation and poster detail DR-18’s ability to re-animate exhausted NK cells, bias differentiation of T cells toward highly active effectors and expand the population of critical immune cells inside the tumor microenvironment

Global Prior Art, the leading provider of patent research and analytics services, announced that Chris Smyth has joined GPA as Vice President, Business Development, effective June 1, 2020.

Olympus®, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced that it is hosting a live panel discussion about the practice of flexible endoscopy during the COVID-19 pandemic with three leading Otolaryngologists

The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for a rapid COVID-19 antibody test distributed by Virality Diagnostics LLC, manufactured by Biohit (Hefei).

Post-secondary students and recent graduates are facing unique and unprecedented challenges because of COVID-19.

Median Technologies, the Imaging Phenomics Company® announced that Oern Stuge MD, MBA, has joined its Board of Directors, chaired by Oran Muduroglu.

Noxopharm, a clinical-stage Australian drug development company, has announced commencement of its NOXCOVID clinical program with a planned Phase I trial in Europe.

Aadi Bioscience, Inc. (Aadi), a privately held biopharmaceutical company focused on development and commercialization of nab-sirolimus (sirolimus albumin-bound nanoparticles for injectable suspension) in mTOR driven diseases, today announced that the company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the treatment of advanced (metastatic or locally advanced) malignant PEComa

The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company’s common stock, payable September 1, 2020, to holders of the Common Stock of record at the close of business on July 31, 2020

Jellagen, a leader in advanced collagen biomaterials from marine sources, announces the closing of a £1.9m seed equity round to pursue development of products for therapeutic and medical device applications